NCCN 9th Annual Congress: Hematologic Malignancies™

September 19, 2014 to September 20, 2014

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

Target Audience

This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with hematologic malignancies.

Additional information

Supported by educational grants from:

  • Bristol-Myers Squibb
  • Cubist
  • Millennium: The Takeda Oncology Company
  • Novartis Oncology
  • Pfizer
  • Seattle Genetics
  • Sequenta, Inc.
  • Sigma-Tau Pharmaceuticals, Inc.
Course summary
Available credit: 
  • 8.75 Case Manager
  • 8.75 Participation
  • 8.75 Nurse
  • 8.75 Pharmacist
  • 8.75 Physician
  • 8.75 Tumor Registrar
Course opens: 
Course expires: 
Event starts: 
09/19/2014 - 6:00pm EDT
Event ends: 
09/20/2014 - 5:00pm EDT
New York Marriott Marquis
New York, NY
United States

This congress is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for case managers, nurses, pharmacists, tumor registrars, and other health care professionals. Please refer to the complete accreditation details for more information.

Available Credit

  • 8.75 Case Manager
  • 8.75 Participation
  • 8.75 Nurse
  • 8.75 Pharmacist
  • 8.75 Physician
  • 8.75 Tumor Registrar


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing